CA3107624C - Composition for eradicating helicobacter pylori - Google Patents

Composition for eradicating helicobacter pylori Download PDF

Info

Publication number
CA3107624C
CA3107624C CA3107624A CA3107624A CA3107624C CA 3107624 C CA3107624 C CA 3107624C CA 3107624 A CA3107624 A CA 3107624A CA 3107624 A CA3107624 A CA 3107624A CA 3107624 C CA3107624 C CA 3107624C
Authority
CA
Canada
Prior art keywords
formula
compound
amount
clarithromycin
amoxicillin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3107624A
Other languages
English (en)
French (fr)
Other versions
CA3107624A1 (en
Inventor
Bong Tae Kim
Dongkyu Kim
Eun Ji Kim
Ji Won Lee
Kyeongmin OH
Ahrong KIM
Geun Seog Song
Shin-Young RYU
Eun Kyung Kim
Naree SHIN
Hyun Ji Kang
Jae Min Kim
Yu-Gyeong PARK
Haneul JEONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HK Inno N Corp
Original Assignee
HK Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HK Inno N Corp filed Critical HK Inno N Corp
Publication of CA3107624A1 publication Critical patent/CA3107624A1/en
Application granted granted Critical
Publication of CA3107624C publication Critical patent/CA3107624C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3107624A 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori Active CA3107624C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0102250 2018-08-29
KR20180102250 2018-08-29
PCT/KR2019/011017 WO2020045992A1 (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Publications (2)

Publication Number Publication Date
CA3107624A1 CA3107624A1 (en) 2020-03-05
CA3107624C true CA3107624C (en) 2023-10-03

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3107624A Active CA3107624C (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Country Status (27)

Country Link
US (2) US20210196685A1 (enExample)
EP (1) EP3843723B1 (enExample)
JP (1) JP7189327B2 (enExample)
KR (1) KR20200026118A (enExample)
CN (1) CN112638378A (enExample)
AR (1) AR116026A1 (enExample)
AU (1) AU2019328903B2 (enExample)
CA (1) CA3107624C (enExample)
DK (1) DK3843723T3 (enExample)
EA (1) EA202190622A1 (enExample)
ES (1) ES3060114T3 (enExample)
FI (1) FI3843723T3 (enExample)
GE (2) GEP20227431B (enExample)
HR (1) HRP20260170T1 (enExample)
JO (1) JOP20190201B1 (enExample)
LT (1) LT3843723T (enExample)
MX (1) MX2021002278A (enExample)
MY (1) MY195494A (enExample)
PH (1) PH12021550385A1 (enExample)
PT (1) PT3843723T (enExample)
RS (1) RS67791B1 (enExample)
SG (1) SG11202101920WA (enExample)
SI (1) SI3843723T1 (enExample)
SM (1) SMT202600153T1 (enExample)
UA (1) UA126993C2 (enExample)
UY (1) UY38348A (enExample)
WO (1) WO2020045992A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3955927A4 (en) * 2019-04-18 2023-06-07 Thomas Julius Borody COMPOSITIONS AND METHODS FOR TREATING, AMOUNTING AND PREVENTING H. PYLORI INFECTIONS
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
BR122020004679B1 (pt) 2005-12-19 2021-09-21 Raqualia Pharma Inc Composição farmacêutica
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
RU2672248C1 (ru) * 2015-06-08 2018-11-13 СиДжей ХЕЛТКЕР КОРПОРЕЙШН Применение производного бензимидазола для лечения ночного кислотного прорыва
WO2017125912A1 (en) * 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
EP3843723A4 (en) 2022-06-29
AU2019328903A1 (en) 2021-04-29
JP2021535910A (ja) 2021-12-23
AU2019328903B2 (en) 2023-01-05
SG11202101920WA (en) 2021-04-29
HRP20260170T1 (hr) 2026-05-08
UA126993C2 (uk) 2023-03-01
CN112638378A (zh) 2021-04-09
PH12021550385A1 (en) 2021-09-20
FI3843723T3 (fi) 2026-02-12
BR112021003578A2 (pt) 2021-05-18
EP3843723B1 (en) 2026-01-07
LT3843723T (lt) 2026-03-25
EP3843723A1 (en) 2021-07-07
GEAP202215593A (en) 2022-07-11
GEP20227431B (en) 2022-10-25
DK3843723T3 (da) 2026-02-09
US20210196685A1 (en) 2021-07-01
RS67791B1 (sr) 2026-03-31
CA3107624A1 (en) 2020-03-05
SMT202600153T1 (it) 2026-05-12
MX2021002278A (es) 2021-08-11
ES3060114T3 (enExample) 2026-03-25
PT3843723T (pt) 2026-01-27
JOP20190201B1 (ar) 2024-04-18
WO2020045992A1 (en) 2020-03-05
US20250241897A1 (en) 2025-07-31
EA202190622A1 (ru) 2021-06-10
AU2019328903A8 (en) 2021-05-27
SI3843723T1 (sl) 2026-04-30
JP7189327B2 (ja) 2022-12-13
KR20200026118A (ko) 2020-03-10
MY195494A (en) 2023-01-26
AR116026A1 (es) 2021-03-25
JOP20190201A1 (ar) 2020-02-29
UY38348A (es) 2020-03-31

Similar Documents

Publication Publication Date Title
US20250241897A1 (en) Composition for eradicating helicobacter pylori
EP3006038B1 (en) Single doses of oritavancin for treating or preventing a bacterial infection
US11938123B2 (en) Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers
JP2018516951A (ja) 夜間胃酸過分泌に対するベンズイミダゾール誘導体の使用
KR20250090275A (ko) 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물
EP4628081A1 (en) Composition for removing helicobacter pylori comprising zastaprazan or pharmaceutically acceptable salt thereof
WO2024204147A1 (ja) 重症熱性血小板減少症候群ウイルス感染症治療剤
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
RU2195937C1 (ru) Комбинированный противотуберкулезный препарат (ризобутол)
JP6042886B2 (ja) 早漏症治療用の薬学組成物
EA043853B1 (ru) Композиция для эрадикации helicobacter pylori
CN109223778B (zh) C24h24n6o2s3在制备抗结核菌药物中的用途
Jibril et al. An open, comparative evaluation of amoxycillin and amoxycillin plus clavulanic acid (‘Augmentin’) in the treatment of bacterial pneumonia in children
JP3937448B2 (ja) Ｈ．ｐｙｌｏｒｉに起因する胃腸障害の処置のためのスピラマイシンの使用
KR20230027226A (ko) 화학요법-유발 설사를 치료하기 위한 방법 및 조성물
BR112021003578B1 (pt) Composição e método para erradicar helicobacter pylori
CN112451678B (zh) HMG-CoA还原酶抑制剂-维D的药物组合物及用途
JP2025538641A (ja) ザスタプラザンまたはこの薬剤学的に許容される塩を含むヘリコバクター・ピロリ除菌用組成物
WO2026009952A1 (ja) 重症熱性血小板減少症候群ウイルス感染症治療剤
KR20240077665A (ko) Prd-2001을 포함하는 암 예방 또는 치료용 약학적 조성물
TW202448422A (zh) 末梢神經障礙之治療或預防用的醫藥
CN114558009A (zh) 一种由阿莫西林和西咪替丁制备的复方制剂及制备方法
JP2025528218A (ja) ピロリ菌（Ｈ．ｐｙｌｏｒｉ）感染症を予防または処置する方法
CN120379674A (zh) 脉管畸形用药物组合物及脉管畸形的治疗方法
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210125

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702